Vaccines are living or inactivated substances that help the body produce immune responses that may prevent a disease or reduce the severity of the illness. Vacines are primarily used for viral infections like measles, mumps, COVID-19 and polio etc. Conventional vaccines do work, but problems exist that they do not have ideal delivery methods, can degrade before reaching to target site and may have side effects. In response to these challenges, liposomal vaccines that have incorporated lipid based nanoparticles have been developed. Antigens and adjuvants encapsulated in liposomes induce the same immune responses as in case of infection and in this way liposomes work as adjuvant of vaccines. Liposome-based vaccines are being developed to address new infectious diseases, improve immunogenicity, and enhance administration methods. They target viral diseases like SARS-CoV-1, RSV, SARS-CoV-2, influenza, HIV dengue fever and Alzheimer's disease. Several formulations that are in clinical trials affirm the prospect of liposomes in forming prophylactic and therapeutic vaccines against the diseases. Currently, liposomal vaccines such as Epaxal for hepatitis A and DepoVax for various diseases are commercially available. These vaccines show that liposomes can be a promising tool for boosting the safety of immunization methods as well as their efficacy thus, liposomes might be used as an improved solution to traditional types of vaccines.